[go: up one dir, main page]

PE20091783A1 - Anticuerpos anti-factor d humanizados - Google Patents

Anticuerpos anti-factor d humanizados

Info

Publication number
PE20091783A1
PE20091783A1 PE2009000572A PE2009000572A PE20091783A1 PE 20091783 A1 PE20091783 A1 PE 20091783A1 PE 2009000572 A PE2009000572 A PE 2009000572A PE 2009000572 A PE2009000572 A PE 2009000572A PE 20091783 A1 PE20091783 A1 PE 20091783A1
Authority
PE
Peru
Prior art keywords
light chain
amino acid
factor
hvr
antibodies
Prior art date
Application number
PE2009000572A
Other languages
English (en)
Inventor
Arthur J Huang
Robert F Kelley
Henry Lowman
Lookeren Campagne Menno Van
Charles M Winter
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40999836&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20091783(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of PE20091783A1 publication Critical patent/PE20091783A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

REFERIDA A UN ANTICUERPO ANTI-FACTOR D QUE COMPRENDE HVR DE CADENA LIGERA DE UN ANTICUERPO DE REFERENCIA QUE COMPRENDE HVR-1 DE CADENA LIGERA QUE CONTIENE ITSTDIDDDMN (SEQ ID NO 30), CADENA LIGERA HVR-2 QUE COMPRENDE GGNTLRP (SEQ ID NO 35) Y CADENA LIGERA HVR-3 QUE COMPRENDE LQSDSLPYT (SEQ ID NO 38) DONDE DICHO ANTICUERPO COMPRENDE UNA SUSTITUCION EN UNA O MAS POSICIONES TALES COMO : EL AMINOACIDO DE LA POSICION 33 DE LA CADENA LIGERA ES L O I, EL AMINOACIDO DE LA POSICION 34 DE LA CADENA LIGERA ES S O A, EL AMINOACIDO DE LA POSICION 1 DE LA CADENA PESADA ES E, EL AMINOACIDO DE LA POSICION 99 DE LA CADENA PESADA ES A O Q, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UN POLIPEPTIDO, UN VECTOR, UNA CELULA HUESPED Y UNA FORMULACION FARMACEUTICA
PE2009000572A 2008-04-28 2009-04-27 Anticuerpos anti-factor d humanizados PE20091783A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4843108P 2008-04-28 2008-04-28
US4868908P 2008-04-29 2008-04-29

Publications (1)

Publication Number Publication Date
PE20091783A1 true PE20091783A1 (es) 2009-12-04

Family

ID=40999836

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2009000572A PE20091783A1 (es) 2008-04-28 2009-04-27 Anticuerpos anti-factor d humanizados
PE2013002736A PE20140806A1 (es) 2008-04-28 2009-04-27 Anticuerpos anti-factor d humanizados y sus usos

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2013002736A PE20140806A1 (es) 2008-04-28 2009-04-27 Anticuerpos anti-factor d humanizados y sus usos

Country Status (35)

Country Link
US (7) US8273352B2 (es)
EP (3) EP2283041B1 (es)
JP (2) JP5636359B2 (es)
KR (2) KR101322027B1 (es)
CN (2) CN103724433B (es)
AR (2) AR071510A1 (es)
AU (1) AU2009241348C1 (es)
BR (1) BRPI0907701A2 (es)
CA (2) CA2908470A1 (es)
CL (2) CL2009001001A1 (es)
CO (1) CO6331346A2 (es)
CR (2) CR20170001A (es)
CY (1) CY1116982T1 (es)
DK (1) DK2283041T3 (es)
EC (1) ECSP10010637A (es)
ES (1) ES2552817T3 (es)
HK (1) HK1245812A1 (es)
HR (1) HRP20151259T1 (es)
HU (1) HUE026349T2 (es)
IL (3) IL208555A (es)
MA (1) MA32300B1 (es)
MX (2) MX2010011342A (es)
MY (2) MY172433A (es)
NZ (3) NZ603492A (es)
PE (2) PE20091783A1 (es)
PH (1) PH12014500519B1 (es)
PL (1) PL2283041T3 (es)
PT (1) PT2283041E (es)
RS (1) RS54405B1 (es)
RU (1) RU2488594C2 (es)
SG (2) SG10201608305SA (es)
SI (1) SI2283041T1 (es)
TW (3) TWI558413B (es)
WO (1) WO2009134711A1 (es)
ZA (1) ZA201301709B (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2500030B2 (en) 2005-11-04 2018-08-08 Genentech, Inc. Use of complement pathway inhibitors to treat ocular diseases
EP1954718B1 (en) 2005-11-30 2014-09-03 AbbVie Inc. Anti-a globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
DK1976877T4 (en) 2005-11-30 2017-01-16 Abbvie Inc Monoclonal antibodies to amyloid beta protein and uses thereof
MY157948A (en) * 2006-11-02 2016-08-30 Genentech Inc Humanized anti-factor d antibodies
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
US20110165648A1 (en) 2009-11-04 2011-07-07 Menno Van Lookeren Campagne Co-crystal structure of factor D and anti-factor D antibody
ES2684475T3 (es) * 2010-04-15 2018-10-03 Abbvie Inc. Proteínas que se unen a beta amiloide
CN105348387B (zh) 2010-08-14 2020-08-25 Abbvie 公司 β淀粉样蛋白结合蛋白
AU2012212047A1 (en) * 2011-02-03 2013-08-22 Xoma Technology Ltd. Methods and materials for enhancing functional protein expression in bacteria
EP2689326B1 (en) 2011-03-25 2022-11-16 Intel Corporation Memory fragments for supporting code block execution by using virtual cores instantiated by partitionable engines
EP2783281B1 (en) * 2011-11-22 2020-05-13 Intel Corporation A microprocessor accelerated code optimizer
AR092630A1 (es) 2012-09-19 2015-04-29 Genentech Inc Metodos y composiciones para prevenir la incorporacion erronea de norleucina en proteinas
EA201591176A1 (ru) 2012-12-18 2016-02-29 Новартис Аг Композиции и способы с использованием пептидной метки, связывающейся с гиалуронаном
US10501531B2 (en) 2013-03-13 2019-12-10 Prothena Biosciences Limited Tau immunotherapy
WO2014151043A1 (en) 2013-03-15 2014-09-25 Soft Machines, Inc. A method for emulating a guest centralized flag architecture by using a native distributed flag architecture
ES2753419T3 (es) 2013-06-07 2020-04-08 Univ Duke Inhibidores del factor H del complemento
EA037325B1 (ru) 2013-07-09 2021-03-12 Аннексон, Инк. Антитела против фактора комплемента c1q и их применения
KR20160042438A (ko) * 2013-08-12 2016-04-19 제넨테크, 인크. 보체-연관 상태의 치료를 위한 조성물 및 방법
AU2014332021B2 (en) * 2013-10-07 2020-05-07 Massachusetts Eye And Ear Infirmary Methods of preventing or reducing photoreceptor cell death
MX2016014160A (es) * 2014-05-01 2017-02-16 Genentech Inc Variantes del anticuerpo anti-factor d y sus usos.
US20170290876A1 (en) 2014-06-25 2017-10-12 Novartis Ag Compositions and methods for long acting proteins
EP3160991A2 (en) 2014-06-25 2017-05-03 Novartis AG Compositions and methods for long acting proteins
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
WO2017075252A1 (en) * 2015-10-30 2017-05-04 Genentech, Inc. Anti-factor d antibody variant conjugates and uses thereof
BR112018008673A2 (pt) 2015-10-30 2018-11-27 Genentech, Inc. métodos para medir a atividade do fator d e para determinar a potência de um inibidor do fator d, método de triagem para um inibidor do fator d e kits
HUE054093T2 (hu) 2015-10-30 2021-08-30 Hoffmann La Roche Anti-HtrA1 antitestek és azok alkalmazási eljárásai
EP3368565A1 (en) * 2015-10-30 2018-09-05 H. Hoffnabb-La Roche Ag Anti-factor d antibody formulations
EP3368074A2 (en) * 2015-10-30 2018-09-05 Hoffmann-La Roche AG Anti-factor d antibodies and conjugates
HRP20220064T1 (hr) * 2015-10-30 2022-04-15 F. Hoffmann - La Roche Ag Zglobno modificirani fragmenti protutijela i postupci za pripravu
EP3380518A4 (en) * 2015-11-24 2019-07-31 Annexon, Inc. ANTI-COMPLEMENT FACTOR C1Q FAB FRAGMENTS AND USES THEREOF
CN108712911A (zh) 2015-12-30 2018-10-26 科达制药股份有限公司 抗体及其缀合物
AU2017210042B2 (en) 2016-01-20 2021-01-21 396419 B.C. Ltd. Compositions and methods for inhibiting Factor D
WO2017129064A1 (zh) * 2016-01-28 2017-08-03 成都康弘生物科技有限公司 抗补体因子D的人源化Fab和人源化抗体及其用途
CN109415432B (zh) 2016-05-02 2022-07-08 普罗塞纳生物科学有限公司 Tau免疫疗法
WO2018136827A1 (en) 2017-01-20 2018-07-26 Vitrisa Therapeutics, Inc. Stem-loop compositions and methods for inhibiting factor d
AU2018217720A1 (en) 2017-02-10 2019-09-05 The Trustees Of The University Of Pennsylvania Anti-factor D antibodies and uses thereof
CN106905431B (zh) * 2017-04-10 2020-01-17 旭华（上海）生物研发中心有限公司 抗人补体d因子的单克隆抗体及其用途
US11584790B2 (en) 2017-04-14 2023-02-21 Kodiak Sciences Inc. Complement factor D antagonist antibodies and conjugates thereof
MY206891A (en) 2017-05-02 2025-01-13 Prothena Biosciences Ltd Antibodies recognizing tau
US10865238B1 (en) 2017-05-05 2020-12-15 Duke University Complement factor H antibodies
GB201800620D0 (en) 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide
WO2019169341A1 (en) 2018-03-02 2019-09-06 Kodiak Sciences Inc. Il-6 antibodies and fusion constructs and conjugates thereof
EP3608674A1 (en) * 2018-08-09 2020-02-12 Regeneron Pharmaceuticals, Inc. Methods for assessing binding affinity of an antibody variant to the neonatal fc receptor
US11912784B2 (en) 2019-10-10 2024-02-27 Kodiak Sciences Inc. Methods of treating an eye disorder
WO2023114763A1 (en) 2021-12-13 2023-06-22 Annexon, Inc. Anti-complement factor c1q antibodies with single binding arms and uses thereof
WO2025208782A1 (en) * 2024-04-02 2025-10-09 Linno (Hangzhou) Pharmaceuticals Inc. Cfd-binding antibody fragments and uses thereof

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4946783A (en) 1987-01-30 1990-08-07 President And Fellows Of Harvard College Periplasmic protease mutants of Escherichia coli
US5010182A (en) 1987-07-28 1991-04-23 Chiron Corporation DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides
WO1989005859A1 (en) 1987-12-21 1989-06-29 The Upjohn Company Agrobacterium mediated transformation of germinating plant seeds
US5256642A (en) 1988-04-01 1993-10-26 The Johns Hopkins University Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof
AU4005289A (en) 1988-08-25 1990-03-01 Smithkline Beecham Corporation Recombinant saccharomyces
US6048728A (en) 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
CA2018228C (en) 1989-06-05 1996-02-27 Nancy L. Parenteau Cell culture systems and media
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5508192A (en) 1990-11-09 1996-04-16 Board Of Regents, The University Of Texas System Bacterial host strains for producing proteolytically sensitive polypeptides
US5264365A (en) 1990-11-09 1993-11-23 Board Of Regents, The University Of Texas System Protease-deficient bacterial strains for production of proteolytically sensitive polypeptides
DE122004000008I1 (de) * 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
WO1993006217A1 (en) 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
US5456909A (en) 1992-08-07 1995-10-10 T Cell Sciences, Inc. Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo
DE69315847T2 (de) 1992-08-21 1998-06-25 Genentech Inc Verfahren zur behandlung einer durch lfa-1 vermittelten störung
US5861156A (en) 1993-01-08 1999-01-19 Creative Biomolecules Methods of delivering agents to target cells
US5856300A (en) 1994-05-12 1999-01-05 T Cell Sciences, Inc. Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions
US5679546A (en) 1993-09-24 1997-10-21 Cytomed, Inc. Chimeric proteins which block complement activation
US5627264A (en) 1994-03-03 1997-05-06 Alexion Pharmaceuticals, Inc. Chimeric complement inhibitor proteins
AU2191795A (en) 1994-03-23 1995-10-09 Alexion Pharmaceuticals, Inc. Method for reducing immune and hemostatic dysfunctions during extracorporeal circulation
US5534615A (en) * 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5679345A (en) 1994-06-02 1997-10-21 The Johns Hopkins University Method for preventing complement-dependent rejection of organ or tissue transplants
WO2000053758A2 (en) 1999-03-08 2000-09-14 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US5681736A (en) 1994-10-05 1997-10-28 Antex Biologics, Inc. Methods for producing enhanced antigenic shigella bacteria and vaccines comprising same
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5639635A (en) 1994-11-03 1997-06-17 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US6027888A (en) 1996-04-05 2000-02-22 Board Of Regents, The University Of Texas System Methods for producing soluble, biologically-active disulfide-bond containing eukaryotic proteins in bacterial cells
WO2002000690A2 (en) 2000-06-23 2002-01-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
US20050197285A1 (en) 1997-03-07 2005-09-08 Rosen Craig A. Human secreted proteins
WO1999040100A1 (en) 1998-02-09 1999-08-12 Human Genome Sciences, Inc. 45 human secreted proteins
US6472520B2 (en) 1997-03-21 2002-10-29 The Trustees Of Columbia University In The City Of New York Rat PEG-3 promoter
US6083715A (en) 1997-06-09 2000-07-04 Board Of Regents, The University Of Texas System Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells
US6333034B1 (en) 1997-08-26 2001-12-25 Gliatech, Inc. Process for inhibiting complement activation via the alternative pathway
US6410708B1 (en) 1997-11-21 2002-06-25 Genentech, Inc. Nucleic acids encoding A-33 related antigen polypeptides
US7419663B2 (en) 1998-03-20 2008-09-02 Genentech, Inc. Treatment of complement-associated disorders
US7192589B2 (en) 1998-09-16 2007-03-20 Genentech, Inc. Treatment of inflammatory disorders with STIgMA immunoadhesins
US8007798B2 (en) 1997-11-21 2011-08-30 Genentech, Inc. Treatment of complement-associated disorders
US8088386B2 (en) 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders
US7282565B2 (en) 1998-03-20 2007-10-16 Genentech, Inc. PRO362 polypeptides
ES2305608T3 (es) 1997-11-21 2008-11-01 Genentech, Inc. Antigenos tipo a-33 y sus utilizaciones farmacologicas.
US6956107B2 (en) * 1998-02-20 2005-10-18 Tanox, Inc. Inhibitors of complement activation
AU762050B2 (en) 1998-02-20 2003-06-19 Genentech, Inc. Inhibitors of complement activation
US7112327B2 (en) 1998-02-20 2006-09-26 Tanox, Inc. Inhibition of complement activation
NZ507435A (en) 1998-03-10 2003-12-19 Genentech Inc Novel polypeptides and nucleic acids with homology to cornichon
EP1108019A2 (en) 1998-08-27 2001-06-20 Incyte Pharmaceuticals, Inc. Protein transport-associated molecules
KR100468977B1 (ko) 1998-12-16 2005-02-02 제넨테크, 인크. 분비 및 막횡단 폴리펩티드, 및 이를 코딩하는 핵산
CA2353799A1 (en) 1998-12-22 2000-06-29 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
ES2694002T3 (es) 1999-01-15 2018-12-17 Genentech, Inc. Polipéptido que comprende una región Fc de IgG1 humana variante
WO2000053749A2 (en) 1999-03-11 2000-09-14 Rmf Dictagene S.A. Vascular adhesion molecules and modulation of their function
US6642353B1 (en) 1999-03-17 2003-11-04 Chugai Seiyaku Kabushiki Kaisha Peptide ligands for the erythropoietin receptor
AU2883900A (en) 1999-07-07 2001-01-30 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1234030A4 (en) 1999-11-19 2003-05-07 Human Genome Sciences Inc 18 HUMAN SECRETED PROTEINS
CA2496312A1 (en) 1999-12-01 2001-06-07 Kevin P. Baker Colon tumour marker pro4799 polypeptides and nucleic acids encoding the same
US6821775B1 (en) 2000-02-11 2004-11-23 Genvec, Inc. Viral vector encoding pigment epithelium-derived factor
ES2329010T3 (es) 2000-03-23 2009-11-20 Genentech, Inc. Inhibidores anti-c2/c2a de la activacion del complemento.
ES2316446T3 (es) 2000-04-29 2009-04-16 University Of Iowa Research Foundation Diagnostico y terapeutica para trastornos relacionados con la degeneracion macular.
EP1309685A2 (en) 2000-07-20 2003-05-14 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
ATE449791T1 (de) 2000-10-10 2009-12-15 Genentech Inc Inhibierung von c5 komplement-aktivierung für die behandlung und vorbeugung von xeno-transplantat oder akute vaskuläre abstossung
NZ525793A (en) 2000-10-13 2008-04-30 Biogen Idec Inc Humanized anti-LT-beta-R antibodies
US20040077575A1 (en) 2002-01-11 2004-04-22 Giordano Giovan Giacomo Inhibition of pathological angiogenesis in vivo
MXPA04001301A (es) 2001-08-17 2004-07-08 Tanox Inc Inhibidores de la ruta del complemento que se unen a c5 y c5a son evitar la formacion de c5b.
TWI323265B (en) * 2002-08-06 2010-04-11 Glaxo Group Ltd Antibodies
WO2004022594A2 (en) 2002-09-06 2004-03-18 Cytos Biotechnology Ag Immune modulatory compounds and methods
US7816497B2 (en) 2002-10-30 2010-10-19 University Of Kentucky Compositions and methods for inhibiting drusen complement components C3a and C5a for the treatment of age-related macular degeneration
RU2232991C1 (ru) 2003-04-09 2004-07-20 Государственное учреждение "Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н. Габричевского" Способ определения функциональной активности фактора d комплемента человека
US7709610B2 (en) * 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
WO2005014849A2 (en) 2003-07-03 2005-02-17 Euro-Celtique, S.A. Genes associated with responses to neuropathic pain
WO2005025509A2 (en) 2003-09-11 2005-03-24 Board Of Regents, The University Of Texas System Methods and materials for treating autoimmune diseases and conditions
US20050169921A1 (en) * 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease
US7127355B2 (en) 2004-03-05 2006-10-24 Perlegen Sciences, Inc. Methods for genetic analysis
US7794713B2 (en) * 2004-04-07 2010-09-14 Lpath, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
CA2588270A1 (en) 2004-11-18 2006-06-15 Yale University Methods and compositions for treating ocular disorders
WO2006071856A2 (en) 2004-12-23 2006-07-06 Glycofi, Inc. Immunoglobulins comprising predominantly a man5glcnac2 glycoform
WO2006088950A2 (en) 2005-02-14 2006-08-24 University Of Iowa Research Foundation Methods and reagents for treatment and diagnosis of age-related macular degeneration
CN103060449A (zh) 2005-06-08 2013-04-24 匹兹堡大学 染色体10q26上的年龄-相关黄斑病变(ARM)易感基因
CN101325963B (zh) 2005-10-08 2016-01-27 博泰迪亚制药公司 用于眼部病症的补体抑制素和其类似物
EP2500030B2 (en) 2005-11-04 2018-08-08 Genentech, Inc. Use of complement pathway inhibitors to treat ocular diseases
US20070190057A1 (en) 2006-01-23 2007-08-16 Jian Wu Methods for modulating mannose content of recombinant proteins
MY157948A (en) * 2006-11-02 2016-08-30 Genentech Inc Humanized anti-factor d antibodies
US20090111708A1 (en) 2007-05-11 2009-04-30 Seddon Johanna M Polynucleotides associated with age-related macular degeneration and methods for evaluating patient risk
AR066660A1 (es) * 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
WO2009146204A1 (en) 2008-04-18 2009-12-03 Tufts Medical Center Polymorphisms associated with age-related macular degeneration and methods for evaluating patient risk
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
US20120003641A1 (en) 2008-11-05 2012-01-05 Graham Robert R Genetic polymorphisms in age-related macular degeneration
WO2010075519A2 (en) 2008-12-23 2010-07-01 Massachusetts Eye & Ear Infirmary Allelic variants associated with advanced age-related macular degeneration
WO2010085542A2 (en) 2009-01-23 2010-07-29 Novartis Ag Biomarkers related to age-related macular degeneration (amd)
US20110165648A1 (en) * 2009-11-04 2011-07-07 Menno Van Lookeren Campagne Co-crystal structure of factor D and anti-factor D antibody
JP5651527B2 (ja) * 2011-05-02 2015-01-14 沖電気工業株式会社 無線端末装置、無線通信システム、プログラムおよび無線通信方法

Also Published As

Publication number Publication date
AR071510A1 (es) 2010-06-23
CY1116982T1 (el) 2017-04-05
PH12014500519B1 (en) 2019-06-28
AU2009241348A1 (en) 2009-11-05
NZ603492A (en) 2014-05-30
KR101322027B1 (ko) 2013-10-30
WO2009134711A8 (en) 2010-10-21
CA2720853A1 (en) 2009-11-05
JP2011521623A (ja) 2011-07-28
PH12014500519A1 (en) 2017-12-11
HK1193111A1 (zh) 2014-09-12
CR11817A (es) 2011-01-13
SG10201608305SA (en) 2016-11-29
MY162350A (en) 2017-06-15
TW200944234A (en) 2009-11-01
CN102066419A (zh) 2011-05-18
EP2283041A1 (en) 2011-02-16
HK1245812A1 (en) 2018-08-31
KR20130084330A (ko) 2013-07-24
IL208555A (en) 2017-09-28
TW201819418A (zh) 2018-06-01
HUE026349T2 (en) 2016-06-28
EP2283041B1 (en) 2015-09-02
US9676868B2 (en) 2017-06-13
WO2009134711A1 (en) 2009-11-05
CO6331346A2 (es) 2011-10-20
PE20140806A1 (es) 2014-07-17
TWI558413B (zh) 2016-11-21
CN103724433B (zh) 2015-11-18
HK1147503A1 (en) 2011-08-12
DK2283041T3 (da) 2015-12-07
ECSP10010637A (es) 2010-12-30
CL2018000537A1 (es) 2018-07-20
US20180100024A1 (en) 2018-04-12
EP3235829A1 (en) 2017-10-25
PL2283041T3 (pl) 2016-01-29
US8273352B2 (en) 2012-09-25
EP3235829B1 (en) 2019-05-22
SI2283041T1 (sl) 2015-12-31
US20190185579A1 (en) 2019-06-20
JP5931008B2 (ja) 2016-06-08
TWI616456B (zh) 2018-03-01
ZA201301709B (en) 2023-01-25
JP5636359B2 (ja) 2014-12-03
US20120328613A1 (en) 2012-12-27
RS54405B1 (sr) 2016-04-28
MA32300B1 (fr) 2011-05-02
MX2010011342A (es) 2010-12-06
JP2013231045A (ja) 2013-11-14
CA2720853C (en) 2015-12-29
PT2283041E (pt) 2015-11-24
CA2908470A1 (en) 2009-11-05
AU2009241348B2 (en) 2012-11-15
RU2488594C2 (ru) 2013-07-27
AR086272A2 (es) 2013-12-04
IL253014A0 (en) 2017-08-31
US20090269338A1 (en) 2009-10-29
CN103724433A (zh) 2014-04-16
US8614306B2 (en) 2013-12-24
AU2009241348C1 (en) 2013-03-28
IL266039A (en) 2019-06-30
EP3002295A1 (en) 2016-04-06
CN102066419B (zh) 2014-07-02
CR20170001A (es) 2017-08-10
MX2018013087A (es) 2020-09-02
RU2010148423A (ru) 2012-06-10
SG189756A1 (en) 2013-05-31
NZ588457A (en) 2012-12-21
CL2009001001A1 (es) 2010-05-14
ES2552817T3 (es) 2015-12-02
IL208555A0 (en) 2010-12-30
US20160145349A1 (en) 2016-05-26
MY172433A (en) 2019-11-25
HRP20151259T1 (hr) 2015-12-18
NZ621103A (en) 2015-10-30
US20140212433A1 (en) 2014-07-31
TW201437230A (zh) 2014-10-01
US20140065137A1 (en) 2014-03-06
KR20110004451A (ko) 2011-01-13
BRPI0907701A2 (pt) 2019-12-10

Similar Documents

Publication Publication Date Title
PE20091783A1 (es) Anticuerpos anti-factor d humanizados
PE20120340A1 (es) Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y melfalan
PE20091352A1 (es) Composicion que comprende anticuerpo que se fija al dominio ii de her2, y sus variantes acidas
CL2012000063A1 (es) Polipéptido factor ix (fix) o un fragmento del mismo porque comprende la modificación de un aminoácido; vector; célula; método para expresar el polipéptido fix; composición farmacéutica; uso de la composición para tratar enfermedades trombóticas, hemorrágicas y coagulación intravascular diseminada (cid) (div. sol. 1796-07).
PE20071111A1 (es) Metodos para modular el contenido de manosa de proteinas recombinantes
EA201590545A1 (ru) Полипептиды, содержащие fc с измененным гликозилированием и сниженной эффекторной функцией
PE20141151A1 (es) Proteinas de union al antigeno cd27l
PE20171512A1 (es) Anticuerpos anti-fap
NZ630885A (en) Antibody formulation
PE20142407A1 (es) Formulacion de anticuerpos
CL2009000166A1 (es) Polipeptido de fusion que comprende un subdominio de la proteina klotho y el factor de crecimiento de fibroblastos; composicion farmaceutica que contiene el polipeptido; acido nucleico; vector y celula huesped que lo contiene; uso de esta composicion para tratar condiciones mediadas por el envejecimiento.
PE20121360A1 (es) Anticuerpos neutralizadores contra el receptor de prolactina
PE20140190A1 (es) Moduladores de proteinas notum y metodos de uso
BR112012021327A2 (pt) anticorpo monoclonal anti-her2 completamente humano, método de preparação e uso do mesmo.
CL2011002756A1 (es) Anticuerpo que se enlaza a la proteina del complemento c3b humana o de cinomolgo; composicion farmaceutica, acido nucleico, vector y celula huesped que comprenden dicho anticuerpo; uso para tratar degeneracion macular relacionada con la edad.
PE20110593A1 (es) Anticuerpos multiespecificos
CL2012003077A1 (es) Polipeptido que comprende el decimo dominio de fibronectina tipo iii (10fn3), en donde el dominio 10fn3 se une al dominio 1 o 2 de seroalbumina humana, y donde la vida media del suero del polipéptido en presencia de seroalbumina es al menos 5 veces mayor que en su ausencia; acido nucleico que lo codifica; vector que lo comprende; celula hospedera que lo expresa; composición que lo comprende; y su uso para tratar la diabetes.
ES2531385T3 (es) Formulación que comprende un anticuerpo contra la selectina P
CL2008000912A1 (es) Proteina insecticida hibrida que comprende dos proteinas cry del bacillus thuringiensis (bt) diferentes; molecula de acido nucleico que comprende dicha proteina; casete de expresion, vector recombinante que comprenden el acido nucleico; celula transg
PE20120914A1 (es) Compuestos glucagon activo de receptor de gip
CL2011000086A1 (es) Anticuerpo aislado o proteina funcional contra el polipeptido baffr que inhibe la proliferacion de celulas b; secuencia nucleotidicas de dicho anticuerpo; vector y celula huesped que comprende dicha secuencia; y su uso para tratar enfermedades autoinmunes o neoplasias de celulas b.
NZ705178A (en) Anti-prolactin receptor antibody formulations
PE20160507A1 (es) Diferenciacion de celulas madre mesenquimales
CL2012000806A1 (es) Anticuerpo anti-guanililo ciclasa c (gcc); inmunoconjugado de dicho anticuerpo; celula, vector y metodo de produccion; composicion que comprende el anticuerpo, uso del anticuerpo o composicion para preparar un medicamento para tratar cancer, particularmente del sistema gastrointestinal.
ES2691539T3 (es) Luciferasas de Oplophorus sintéticas con mayor emisión de luz

Legal Events

Date Code Title Description
FG Grant, registration